Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Bauer

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
JAMA|February 15, 2001
Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adultsT M Bauer, A Lalvani, J Fehrenbach, et al.
Journal of Hepatology|February 24, 2001
Bacterial translocation of enteric organisms in patients with cirrhosisI Cirera, T M Bauer, M Navasa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIsE Felip, A T Shaw, A Bearz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2017
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumorsY J Bang, G Giaccone, S A Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN studyA T Shaw, B J Solomon, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trialM Schuler, R Berardi, W-T Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2021
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer<sup>☆</sup>J Niu, C Maurice-Dror, D H Lee, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
JAMA|February 15, 2001
Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adultsT M Bauer, A Lalvani, J Fehrenbach, et al.
Journal of Hepatology|February 24, 2001
Bacterial translocation of enteric organisms in patients with cirrhosisI Cirera, T M Bauer, M Navasa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIsE Felip, A T Shaw, A Bearz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2017
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumorsY J Bang, G Giaccone, S A Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN studyA T Shaw, B J Solomon, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trialM Schuler, R Berardi, W-T Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2021
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer<sup>☆</sup>J Niu, C Maurice-Dror, D H Lee, et al.
Pageof 3